Glaukos slumps after reaffirming annual net sales forecast

Glaukos

13/01/2026 22:22

** Shares of medtech firm Glaukos GKOS.N down 12% at $97 in extended trading

**  Reaffirms its 2026 net sales guidance in the range of $600 million to $620 million

**  Projects preliminary full-year 2025 net sales of $507 million, compared to previous projection of $490 million to $495 million

** Expects Q4 net sales rise of 36% at $143 million vs estimates of $129.5 million - data compiled by LSEG

** GKOS will report Q4 and full-year results on February 17

** Shares fell ~25% in 2025

​

 (Reporting by Koyena Das in Bengaluru)

 ((koyena.das@thomsonreuters.com))